 The phase 1b dose-escalation portion of the trial is expected to begin Q1 2016. Patients will be sequentially enrolled to dose-escalation cohorts until establishment of the Maximum Tolerated Dose MTD and Recommended Phase 2 Dose RP2D of Sym004 in combination with FOLFIRI. 